Scholar Rock at Leerink Conference: Strategic Path Amid FDA Delays

Scholar Rock secured up to $550M in staged loans (with $100M already repaid) and closed the year with $368M cash, and management reaffirmed a 2026 BLA resubmission and targeted U.S. launch of Apitegromab pending a positive FDA re-inspection. The sole approvability issue remains third‑party fill/finish compliance at the former Catalent/Novo Nordisk Bloomington site—FDA engagement has resumed, routine manufacturing restarted, and a second fill‑finish facility has engineering/PPQ runs underway; the company reports tens of thousands of vials in inventory to support patients. Commercial preparations include a disease‑education campaign, a ~10,000‑nurse home infusion network, planned Germany launch followed by country‑by‑country reimbursement, and an ambition for a 50‑country operating platform addressing ~35,000 patients who have received SMN‑targeted therapy globally.

Analysis

Concentration of a critical outsourced manufacturing step creates a binary regulatory exposure that markets often underprice. If the regulator signals a clean re-inspection within the next 4–8 weeks, the path to approval compresses materially and implied volatility should collapse; if it fails, expect a multi-month remediation timeline that forces sponsors to accelerate qualification of alternate fillers and shifts the cadence of launch spend. Payer friction is the more persistent multi-quarter risk: novel add-on muscle-targeted labels typically face utilization management and step edits that depress first‑year conversion to 30–60% of theoretical addressable patients absent aggressive white‑glove access programs. Finally, the company’s non‑dilutive liquidity and a potential regulatory voucher create optionality that can be monetized to fund commercial scale-up, but markets will re-rate only after clear evidence of both regulatory closure and early access conversion metrics (EAP roll‑rate, payer approvals) over the coming 3–9 months.

Key Decisions for Investors

• Buy SRRK directional exposure via a 9–15 month call spread (long-dated call / sell higher-strike call) sized 1–2% portfolio — entry before the next formal re‑inspection announcement to capture asymmetric upside on an approval/resubmission catalyst while capping premium loss to <100%; target 2.5–4x payoff if approval and early traction occur within 6–9 months, loss = full premium if delayed beyond spread expiry.
• Pair trade: Long SRRK equity (small size 1%) and buy NVO 6–12 month put spread (protective tail, 0.5% notional) — expresses divergence between a single-product upside and counterparty operational/legal downside; this keeps upside exposure while limiting capital at risk if broad regulatory scrutiny expands to the contract manufacturer owner.
• Event-driven hedge: If a formal re‑inspection is scheduled, sell short-dated volatility by selling SRRK near-term strangles (very small size) funded by the call-spread premium, but only after liquidity returns — capture anticipated IV crush on a clean inspection while keeping net directional exposure via the longer-dated call spread.